KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
KNTE
Delisted
KNTE was delisted on the 2nd of April, 2024.
71 hedge funds and large institutions have $270M invested in Kinnate Biopharma Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
-8
Holders Change %
-10.13%
% of All Funds
1.14%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
6
Increased
24
Reduced
22
Closed
14
Calls
$277K
Puts
$74K
Net Calls
+$203K
Net Calls Change
+$203K
Top Buyers
| 1 |
O
OrbiMed
New York
|
$32.1M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
$12.3M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
$6.81M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
$13.8M |
| 5 |
Goldman Sachs
New York
|
$1.37M |
